KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) EBT Margin (2016 - 2025)

Historic EBT Margin for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Q3 2025 value amounting to 39.76%.

  • Rigel Pharmaceuticals' EBT Margin rose 173000.0% to 39.76% in Q3 2025 from the same period last year, while for Sep 2025 it was 40.53%, marking a year-over-year increase of 380700.0%. This contributed to the annual value of 10.24% for FY2024, which is 317100.0% up from last year.
  • Latest data reveals that Rigel Pharmaceuticals reported EBT Margin of 39.76% as of Q3 2025, which was up 173000.0% from 58.99% recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' EBT Margin registered a high of 58.99% during Q2 2025, and its lowest value of 164.0% during Q1 2022.
  • For the 5-year period, Rigel Pharmaceuticals' EBT Margin averaged around 24.32%, with its median value being 20.23% (2023).
  • The largest annual percentage gain for Rigel Pharmaceuticals' EBT Margin in the last 5 years was 1139600bps (2022), contrasted with its biggest fall of -2149400bps (2022).
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' EBT Margin stood at 111.23% in 2021, then soared by 102bps to 2.73% in 2022, then dropped by -25bps to 2.06% in 2023, then skyrocketed by 1184bps to 26.43% in 2024, then surged by 50bps to 39.76% in 2025.
  • Its last three reported values are 39.76% in Q3 2025, 58.99% for Q2 2025, and 21.58% during Q1 2025.